Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients
← catalyst calendarSponsored by Alligator Bioscience AB (industry) · ATORX.ST — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
94actual
Sites
14
Countries
Belgium, France, Spain
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-09-17 | actual | When the study began enrolling |
| Primary completion | 2026-06-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2021-05-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Pancreatic Ductal Adenocarcinoma
Intervention
- Biological: CD40 agonist mitazalimab in combination with chemotherapy — also filed as ADC-1013, JNJ-64457107
Primary outcomes
what the primary-completion date above is the date OFIncidence of Dose Limiting Toxicities (DLTs) (Part 1: Phase 1b Dose escalation)
measured From first dose to end of dose limiting toxicity period (Day 1-21)
Objective response rate (ORR) (Part 2: Phase 2 Dose expansion)
measured From first dose to 28-56 days after end of study treatment
Publications
- PMID 41061701 — linked by the registry
- PMID 38834087 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ATORX.ST's whole pipeline · Catalyst calendar · Every registered study · What changed